Profile of:

Carlos Gonzalez-Fernandez


Full name: Carlos Gonzalez-Fernandez

Current country: Spain

Membership level: Full

Type of membership: Member

Number of publications: 36

Long-Term Retention Rate of Golimumab in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis in a Real-Life Setting. (2022)
https://doi.org/10.1097/RHU.0000000000001695

Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study. (2021)
https://europepmc.org/articles/PMC8021319

Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. (2020)
https://doi.org/10.1007/s12325-020-01585-7

Patients’ perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEU‐LIFE survey (2020)
https://doi.org/10.1002/msc.1499

Patients’ perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEU‐LIFE survey (2020)
https://doi.org/10.1002/msc.1499

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. (2020)
https://europepmc.org/articles/PMC7161121

Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. (2018)
https://doi.org/10.1136/annrheumdis-2018-214158

Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology. (2018)
https://doi.org/10.1016/j.reuma.2018.09.008

Assessment of SpondyloArthritis International Society (ASAS) Consensus on Spanish Nomenclature for Spondyloarthritis. (2018)
https://doi.org/10.1016/j.reuma.2018.07.014

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. (2018)
https://doi.org/10.1016/s0140-6736(18)30952-8

Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. (2017)
https://doi.org/10.1016/j.reuma.2017.03.011

Recommendations for the Use of Ultrasound and Magnetic Resonance in Patients With Spondyloarthritis, Including Psoriatic Arthritis, and Patients With Juvenile Idiopathic Arthritis. (2017)
https://doi.org/10.1016/j.reuma.2016.08.008

Perceptions of patients with rheumatic diseases treated with subcutaneous biologicals on their level of information: RHEU-LIFE Survey. (2017)
https://doi.org/10.1016/j.reuma.2017.11.006

Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. (2017)
https://europepmc.org/articles/PMC5530861

Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain. (2015)
https://doi.org/10.1016/j.jval.2015.09.2313

Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis Patients In Spain. (2015)
https://doi.org/10.1016/j.jval.2015.09.2308

A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. (2015)
https://doi.org/10.1136/annrheumdis-2014-207190

Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. (2015)
https://doi.org/10.1007/s10067-015-2880-7

Two-year incidence of psoriasis, uveitis and inflammatory bowel disease in patients with spondyloarthritis: A study in the AQUILES cohort. (2015)
https://doi.org/10.1016/j.reuma.2015.01.002

Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis. (2014)
https://doi.org/10.1007/s00296-014-3180-2

Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study. (2014)
https://doi.org/10.1016/j.reuma.2014.04.003

PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. (2014)
https://www.futuremedicine.com/doi/10.2217/pgs.14.125

Comparison of 2 referral strategies for the diagnosis of axial spondyloarthritis in Spain. The RADAR study. (2013)
https://doi.org/10.1016/j.reuma.2013.02.009

High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). (2011)
https://doi.org/10.1093/rheumatology/ker083

Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. (2011)
https://doi.org/10.3899/jrheum.100851

[Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients]. (2011)
https://doi.org/10.1016/j.reuma.2011.05.002

Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. (2010)
https://pubmed.ncbi.nlm.nih.gov/21176420/

Relationship between spinal mobility and disease activity, function, quality of life and radiology. A cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). (2009)
https://pubmed.ncbi.nlm.nih.gov/19604436/

Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. (2007)
https://doi.org/10.1093/rheumatology/kem084

[Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNFα en las espondiloartritis, incluida la artritis psoriásica]. (2007)
https://doi.org/10.1016/s1699-258x(07)73645-8

[Estudio 3(e)]. (2007)
https://doi.org/10.1016/s1699-258x(07)73641-0

Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. (2005)
https://doi.org/10.1093/rheumatology/kei085

Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. (2003)
https://doi.org/10.1136/ard.2002.004879

Clinical significance of abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondyloarthropathies. (2000)
https://doi.org/10.1007/s002590000393

Abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondylarthropathies without clinical evidence of inflammatory bowel disease. (1996)
https://doi.org/10.1007/bf00837621

Different abdominal scintigraphy pattern in patients with ulcerative colitis, Crohn’s disease and seronegative spondylarthropathies. (1995)
https://doi.org/10.1093/rheumatology/34.10.946